BACKGROUND AND OBJECTIVES: Both prolactin clearance and production are altered in CKD. In nonrenal populations, emerging evidence suggests that prolactin participates in the atherosclerotic process. Given the elevated cardiovascular risk of CKD, this study examined links between prolactinemia, vascular derangements, and outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This observational study was conducted in two cohorts: one with 457 nondialyzed CKD patients (mean age 52±12 years; 229 men) with measurements of flow-mediated dilation (FMD) and carotid intima-media thickness and one with 173 hemodialysis patients (65±12 years; 111 men) with measurements of pulse wave velocity (PWV). Patients were followed for cardiovascular events (n=146, nondialyzed cohort) or death (n=79, hemodialysis cohort). RESULTS: Prolactin levels increased along with reduced kidney function. Prolactin significantly and independently contributed to explain the variance of both FMD (in nondialyzed patients) and PWV (in hemodialysis patients), but not intima-media thickness. In Cox analyses, the risk of cardiovascular events in nondialyzed patients increased by 27% (hazard ratio [HR], 1.27; 95% confidence interval [95% CI], 1.17-1.38) for each 10 ng/ml increment of prolactin. Similarly, the risk for all-cause and cardiovascular mortality in hemodialysis patients increased by 12% (HR, 1.12; 95% CI, 1.06-1.17) and 15% (HR, 1.15; 95% CI, 1.08-1.21), respectively. This was true after multivariate adjustment for confounders and after adjustment within the purported causal pathway (FMD or PWV). CONCLUSIONS: Prolactin levels directly associated with endothelial dysfunction/stiffness and with increased risk of cardiovascular events and mortality in two independent cohorts of CKD patients.
BACKGROUND AND OBJECTIVES: Both prolactin clearance and production are altered in CKD. In nonrenal populations, emerging evidence suggests that prolactin participates in the atherosclerotic process. Given the elevated cardiovascular risk of CKD, this study examined links between prolactinemia, vascular derangements, and outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This observational study was conducted in two cohorts: one with 457 nondialyzed CKDpatients (mean age 52±12 years; 229 men) with measurements of flow-mediated dilation (FMD) and carotid intima-media thickness and one with 173 hemodialysis patients (65±12 years; 111 men) with measurements of pulse wave velocity (PWV). Patients were followed for cardiovascular events (n=146, nondialyzed cohort) or death (n=79, hemodialysis cohort). RESULTS:Prolactin levels increased along with reduced kidney function. Prolactin significantly and independently contributed to explain the variance of both FMD (in nondialyzed patients) and PWV (in hemodialysis patients), but not intima-media thickness. In Cox analyses, the risk of cardiovascular events in nondialyzed patients increased by 27% (hazard ratio [HR], 1.27; 95% confidence interval [95% CI], 1.17-1.38) for each 10 ng/ml increment of prolactin. Similarly, the risk for all-cause and cardiovascular mortality in hemodialysis patients increased by 12% (HR, 1.12; 95% CI, 1.06-1.17) and 15% (HR, 1.15; 95% CI, 1.08-1.21), respectively. This was true after multivariate adjustment for confounders and after adjustment within the purported causal pathway (FMD or PWV). CONCLUSIONS:Prolactin levels directly associated with endothelial dysfunction/stiffness and with increased risk of cardiovascular events and mortality in two independent cohorts of CKDpatients.
Authors: D Raaz; H Wallaschofski; C Stumpf; A Yilmaz; I Cicha; L Klinghammer; W G Daniel; T Lohmann; C D Garlichs Journal: Horm Metab Res Date: 2006-11 Impact factor: 2.936
Authors: Denise Hilfiker-Kleiner; Gerd Peter Meyer; Elisabeth Schieffer; Britta Goldmann; Edith Podewski; Ingrid Struman; Philipp Fischer; Helmut Drexler Journal: J Am Coll Cardiol Date: 2007-11-05 Impact factor: 24.094
Authors: Claudio Molinari; Elena Grossini; David A S G Mary; Francesca Uberti; Ezio Ghigo; Flavio Ribichini; Nicola Surico; Giovanni Vacca Journal: Endocrinology Date: 2007-04-26 Impact factor: 4.736
Authors: Dimitrios Karakitsos; Alexandros P Patrianakos; Eric De Groot; John Boletis; Andreas Karabinis; John Kyriazis; George Samonis; Frangiskos I Parthenakis; Panos E Vardas; Eugene Daphnis Journal: Am J Nephrol Date: 2006-12-06 Impact factor: 3.754
Authors: Juan Jesús Carrero; Abdul Rashid Qureshi; Paolo Parini; Stefan Arver; Bengt Lindholm; Peter Bárány; Olof Heimbürger; Peter Stenvinkel Journal: J Am Soc Nephrol Date: 2009-01-14 Impact factor: 10.121
Authors: George A Georgiopoulos; Kimon S Stamatelopoulos; Irene Lambrinoudaki; Maria Lykka; Katerina Kyrkou; Dimitrios Rizos; Maria Creatsa; George Christodoulakos; Maria Alevizaki; Petros P Sfikakis; Christos Papamichael Journal: Hypertension Date: 2009-05-18 Impact factor: 10.190
Authors: Dinanda J de Jager; Diana C Grootendorst; Kitty J Jager; Paul C van Dijk; Lonneke M J Tomas; David Ansell; Frederic Collart; Patrik Finne; James G Heaf; Johan De Meester; Jack F M Wetzels; Frits R Rosendaal; Friedo W Dekker Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: J J Carrero; A R Qureshi; J Axelsson; M I Yilmaz; S Rehnmark; M R Witt; P Bárány; O Heimbürger; M E Suliman; A Alvestrand; B Lindholm; P Stenvinkel Journal: J Intern Med Date: 2007-10-01 Impact factor: 8.989
Authors: G Georgiopoulos; I Lambrinoudaki; F Athanasouli; E Armeni; A Koliviras; A Augoulea; D Rizos; C Papamichael; A Protogerou; K Stellos; K Stamatelopoulos Journal: J Hum Hypertens Date: 2017-03-23 Impact factor: 3.012
Authors: Silvia Ros; Cesar Remón; Abdul Rashid Qureshi; Pedro Quiros; Bengt Lindholm; Juan Jesús Carrero Journal: Perit Dial Int Date: 2013-10-01 Impact factor: 1.756